Splenectomy suppresses growth and metastasis of hepatocellular carcinoma through decreasing myeloid-derived suppressor cells in vivo

  • Xin Long (龙 新)
  • Jian Wang (王 健)
  • Jian-ping Zhao (赵健萍)
  • Hui-fang Liang (梁慧芳)
  • Peng Zhu (朱 鹏)
  • Qi Cheng (程 琪)
  • Qian Chen (陈 倩)
  • Yan-hui Wu (吴延晦)
  • Zhan-guo Zhang (张占国)
  • Bi-xiang Zhang (张必翔)Email author
  • Xiao-ping Chen (陈孝平)


The function of the spleen in tumor development has been investigated for years. The relationship of the spleen with hepatocellular carcinoma (HCC), a huge health burden worldwide, however, remains unknown. The present study aimed to examine the effect of splenectomy on the development of HCC and the possible mechanism. Mouse hepatic carcinoma lines H22 and Hepa1-6 as well as BALB/c and C57 mice were used to establish orthotopic and metastatic mouse models of liver cancer. Mice were divided into four groups, including control group, splenectomy control group (S group), tumor group (T group) and tumor plus splenectomy group (T+S group). Tumor growth, metastases and overall survival were assessed at determined time points. Meanwhile, myeloid-derived suppressor cells (MDSCs) were isolated from the peripheral blood (PB), the spleen and liver tumors, and then measured by flow cytometery. It was found that liver cancer led to splenomegaly, and increased the percentage of MDSCs in the PB and spleen in the mouse models. Splenectomy inhibited the growth and progression of liver cancer and prolonged the overall survival time of orthotopic and metastatic models, which was accompanied by decreased proportion of MDSCs in the PB and tumors of liver cancer-bearing mouse. It was suggested that splenectomy could be considered an adjuvant therapy to treat liver cancer.


splenectomy liver cancer myeloid-derived suppressor cells adjuvant therapy 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet, 2012,379(9822):1245–1255CrossRefPubMedGoogle Scholar
  2. 2.
    Yong KJ, Gao C, Lim JS, et al. Oncofetal gene SALL4 in aggressive hepatocellular carcinoma. N Engl J Med, 2013,368(24):2266–2276CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Flores A, Marrero JA. Emerging trends in hepatocellular carcinoma: focus on diagnosis and therapeutics. Clin Med Insights Oncol, 2014,8:71–76PubMedPubMedCentralGoogle Scholar
  4. 4.
    Wei KR, Yu X, Zheng RS, et al. Incidence and mortality of liver cancer in China, 2010. Chin J Cancer, 2014,33(8):388–394PubMedPubMedCentralGoogle Scholar
  5. 5.
    Wei S, Hao X, Zhan D, et al. Are surgical indications of Barcelona Clinic Liver Cancer staging classification justified? J Huazhong Univ Sci Technolog Med Sci, 2011,31(5):637–641Google Scholar
  6. 6.
    Wei S, Xiong M, Zhan DQ, et al. Ku80 functions as a tumor suppressor in hepatocellular carcinoma by inducing S-phase arrest through a p53-dependent pathway. Carcinogenesis, 2012,33(3):538–547CrossRefPubMedGoogle Scholar
  7. 7.
    Colovai AI, Giatzikis C, Ho EK, et al. Flow cytometric analysis of normal and reactive spleen. Mod Pathol, 2004,17(8):918–927CrossRefPubMedGoogle Scholar
  8. 8.
    Mebius RE. Kraal G. Structure and function of the spleen. Nat Rev Immunol, 2005,5(8):606–616CrossRefPubMedGoogle Scholar
  9. 9.
    Dieguez-Acuna FJ, Gygi SP, Davis M, et al. Splenectomy: a new treatment option for ALL tumors expressing Hox-11 and a means to test the stem cell hypothesis of cancer in humans. Leukemia, 2007,21(10):2192–2194CrossRefPubMedGoogle Scholar
  10. 10.
    Cortez-Retamozo, V, Etzrodt M, Newton A, et al. Origins of tumor-associated macrophages and neutrophils. Proc Natl Acad Sci USA, 2012,109(7):2491–2496CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Ugel S, Peranzoni E, Desantis G, et al. Immune tolerance to tumor antigens occurs in a specialized environment of the spleen. Cell Rep, 2012,2(3):628–639CrossRefPubMedGoogle Scholar
  12. 12.
    Xia S, Li X, Cheng L, et al. Chronic intake of high fish oil diet induces myeloid-derived suppressor cells to promote tumor growth. Cancer Immunol Immunother, 2014,63(7):663–673CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Shaked Y, Cervi D, Neuman M, et al. The splenic microenvironment is a source of proangiogenesis/inflammatory mediators accelerating the expansion of murine erythroleukemic cells. Blood, 2005,105(11):4500–4507CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Prehn RT. The paradoxical effects of splenectomy on tumor growth. Theor Biol Med Model, 2006,3:23CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Sonoda K, Izumi K, Matsui Y, et al. Decreased growth rate of lung metastatic lesions after splenectomy in mice. Eur Surg Res, 2006,38(5):469–475CrossRefPubMedGoogle Scholar
  16. 16.
    Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell, 2011,144(5):646–674CrossRefPubMedGoogle Scholar
  17. 17.
    Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol, 2009,9(3):162–174CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Damuzzo V, Pinton L, Desantis G, et al. Complexity and challenges in defining myeloid-derived suppressor cells. Cytometry B Clin Cytom, 2015,88(2):77–91CrossRefPubMedGoogle Scholar
  19. 19.
    Chi N, Tan Z, Ma K, et al. Increased circulating myeloid-derived suppressor cells correlate with cancer stages, interleukin-8 and -6 in prostate cancer. Int J Clin Exp Med, 2014,7(10):3181–3192PubMedPubMedCentralGoogle Scholar
  20. 20.
    Li RJ, Liu L, Gao W, et al. Cyclooxygenase-2 blockade inhibits accumulation and function of myeloid-derived suppressor cells and restores T cell response after traumatic stress. J Huazhong Univ Sci Technolog Med Sci, 2014,34(2):234–240CrossRefPubMedGoogle Scholar
  21. 21.
    Zhu XJ, Hu J, Sun L, et al. Amplification of functional myeloid-derived suppressor cells during stem cell mobilization induced by granulocyte colony-stimulationfactor. J Huazhong Univ Sci Technolog Med Sci, 2013,33(6):817–821CrossRefPubMedGoogle Scholar
  22. 22.
    Schmid M, Zimara N, Wege AK, et al. Myeloid-derived suppressor cell functionality and interaction with Leishmania major parasites differ in C57BL/6 and BALB/c mice. Eur J Immunol, 2014,44(11):3295–3306CrossRefPubMedGoogle Scholar
  23. 23.
    Movahedi K, Guilliams M, Van den Bossche J, et al. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cellsuppressive activity. Blood, 2008,111(8):4233–4244CrossRefPubMedGoogle Scholar
  24. 24.
    Youn JI, Nagaraj S, Collazo M, et al. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol, 2008,181(8):5791–5802CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Condamine T, Ramachandran I, Youn JI, et al. Regulation of tumor metastasis by myeloid-derived suppressor cells. Annu Rev Med, 2015,66:97–110CrossRefPubMedGoogle Scholar
  26. 26.
    Youn, JI, Collazo M, Shalova IN, et al. Characterization of the nature of granulocytic myeloid-derived suppressor cells in tumor-bearing mice. J Leukoc Biol, 2012,91(1):167–181CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Murdoc, C, Muthana M, Coffelt SB, et al. The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer, 2008,8(8):618–631CrossRefGoogle Scholar
  28. 28.
    Skabytska Y, Wolbing F, Gunther C, et al. Cutaneous innate immune sensing of toll-like receptor 2-6 ligands suppresses T cell immunity by inducing myeloid-derived suppressor cells. Immunity, 2014,41(5):762–775CrossRefPubMedGoogle Scholar
  29. 29.
    Diaz-Montero CM, Salem ML, Nishimura MI, et al. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother, 2009,58(1):49–59CrossRefPubMedGoogle Scholar
  30. 30.
    Ren M, Ye L, Hao X, et al. Polysaccharides from Tricholoma matsutake and Lentinus edodes enhance 5-fluorouracil-mediated H22 cell growth inhibition. J Tradit Chin Med, 2014,34(3):309–316CrossRefPubMedGoogle Scholar
  31. 31.
    Li P, Feng Z, Zhang G, et al. Inhibitory effect of recombinant endostatin on angiogenesis and tumor growth of hepatoma. J Huazhong Univ Sci Technolog Med Sci, 2003,23(3):223–226CrossRefPubMedGoogle Scholar
  32. 32.
    Qin L, Wang X, Duan Q, et al. Inhibitory effect of melatonin on the growth of H22 hepatocarcinoma cells by inducing apoptosis. J Huazhong Univ Sci Technolog Med Sci, 2004,24(1):19–21, 31CrossRefPubMedGoogle Scholar
  33. 33.
    Zhang B, Halder SK, Zhang S, et al. Targeting transforming growth factor-beta signaling in liver metastasis of colon cancer. Cancer Lett, 2009,277(1):114–120CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Ding ZY, Jin, GN. Wang W, et al. Reduced expression of transcriptional intermediary factor 1 gamma promotes metastasis and indicates poor prognosis of hepatocellular carcinoma. Hepatology, 2014,60(5):1620–1636CrossRefPubMedGoogle Scholar
  35. 35.
    Schwarz RE, Hiserodt JC. Effects of splenectomy on the development of tumor-specific immunity. J Surg Res, 1990,48(5):448–453CrossRefPubMedGoogle Scholar
  36. 36.
    Brooks SP, Rich GA, Huh YS, et al. Lymphoid cell populations in splenectomized and nonsplenectomized SJL/J mice bearing Hodgkin’s disease-like reticulum cell sarcoma. J Pediatr Surg, 1986,21(12):1114–1118CrossRefPubMedGoogle Scholar
  37. 37.
    Miwa H, Kojima K, Kobayashi T, et al. The tumor—immunological significance of splenectomy for cancer therapy. Nihon Geka Gakkai Zasshi, 1983,84(9):970–973PubMedGoogle Scholar
  38. 38.
    Jing-Shi W, Yi-Ni W, Lin W, et al. Splenectomy as a treatment for adults with relapsed hemophagocytic lymphohistiocytosis of unknown cause. Ann Hematol, 2015,94(5):753–760CrossRefPubMedGoogle Scholar
  39. 39.
    Derlatka P, Grabowska-Derlatka L, Sienko J, et al. Splenectomy as a part of debulking surgery in patients with advanced ovarian cancer. Ginekol Pol, 2014,85(8):605–608PubMedGoogle Scholar
  40. 40.
    Santos FP, Tam CS, Kantarjian H, et al. Splenectomy in patients with myeloproliferative neoplasms: efficacy, complications and impact on survival and transformation. Leuk Lymphoma, 2014,55(1):121–127CrossRefPubMedGoogle Scholar
  41. 41.
    Chen XP, Wu ZD, Huang ZY, et al. Use of hepatectomy and splenectomy to treat hepatocellular carcinoma with cirrhotic hypersplenism. Br J Surg, 2005,92(3):334–339CrossRefPubMedGoogle Scholar
  42. 42.
    Solito S, Marigo I, Pinton L, et al. Myeloid-derived suppressor cell heterogeneity in human cancers. Ann N Y Acad Sci, 2014,1319:47–65CrossRefPubMedGoogle Scholar
  43. 43.
    Hochst B, Schildberg FA, Sauerborn P, et al. Activated human hepatic stellate cells induce myeloid derived suppressor cells from peripheral blood monocytes in a CD44-dependent fashion. J Hepatol, 2013,59(3):528–535CrossRefPubMedGoogle Scholar

Copyright information

© Huazhong University of Science and Technology and Springer-Verlag Berlin Heidelberg 2016

Authors and Affiliations

  • Xin Long (龙 新)
    • 1
  • Jian Wang (王 健)
    • 1
  • Jian-ping Zhao (赵健萍)
    • 1
  • Hui-fang Liang (梁慧芳)
    • 1
  • Peng Zhu (朱 鹏)
    • 1
  • Qi Cheng (程 琪)
    • 1
  • Qian Chen (陈 倩)
    • 2
  • Yan-hui Wu (吴延晦)
    • 1
  • Zhan-guo Zhang (张占国)
    • 1
  • Bi-xiang Zhang (张必翔)
    • 1
    Email author
  • Xiao-ping Chen (陈孝平)
    • 1
  1. 1.Hepatic Surgery CenterHuazhong University of Science and TechnologyWuhanChina
  2. 2.Department of Gastroenterology, Tongji Hospital, Tongji Medical CollegeHuazhong University of Science and TechnologyWuhanChina

Personalised recommendations